JP2008538107A - 変異型cftrプロセシングの修正において活性を有する化合物及びその用途 - Google Patents

変異型cftrプロセシングの修正において活性を有する化合物及びその用途 Download PDF

Info

Publication number
JP2008538107A
JP2008538107A JP2008501913A JP2008501913A JP2008538107A JP 2008538107 A JP2008538107 A JP 2008538107A JP 2008501913 A JP2008501913 A JP 2008501913A JP 2008501913 A JP2008501913 A JP 2008501913A JP 2008538107 A JP2008538107 A JP 2008538107A
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
cftr
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008501913A
Other languages
English (en)
Japanese (ja)
Inventor
ヴァークマン,アラン
ペデモンテ,ニコレッタ
ガリエッタ,ルイス,ジェー.ヴィ.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2008538107A publication Critical patent/JP2008538107A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
JP2008501913A 2005-03-18 2006-03-08 変異型cftrプロセシングの修正において活性を有する化合物及びその用途 Withdrawn JP2008538107A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66350105P 2005-03-18 2005-03-18
PCT/US2006/008267 WO2006101740A2 (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-cftr processing and uses thereof

Publications (1)

Publication Number Publication Date
JP2008538107A true JP2008538107A (ja) 2008-10-09

Family

ID=37024308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008501913A Withdrawn JP2008538107A (ja) 2005-03-18 2006-03-08 変異型cftrプロセシングの修正において活性を有する化合物及びその用途

Country Status (12)

Country Link
US (1) US8143295B2 (US20080318984A1-20081225-C00018.png)
EP (1) EP1863522A4 (US20080318984A1-20081225-C00018.png)
JP (1) JP2008538107A (US20080318984A1-20081225-C00018.png)
KR (1) KR20070114820A (US20080318984A1-20081225-C00018.png)
CN (1) CN101605543A (US20080318984A1-20081225-C00018.png)
AU (1) AU2006227833A1 (US20080318984A1-20081225-C00018.png)
BR (1) BRPI0608453A2 (US20080318984A1-20081225-C00018.png)
CA (1) CA2600869A1 (US20080318984A1-20081225-C00018.png)
IL (1) IL185999A0 (US20080318984A1-20081225-C00018.png)
MX (1) MX2007011512A (US20080318984A1-20081225-C00018.png)
RU (1) RU2007138584A (US20080318984A1-20081225-C00018.png)
WO (1) WO2006101740A2 (US20080318984A1-20081225-C00018.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541367A (ja) * 2006-06-27 2009-11-26 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシス ピーエルエイ 2,4,5−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用
JP2017511333A (ja) * 2014-04-03 2017-04-20 ケンブリッジ エンタープライズ リミテド ラミノパシー、老化及び癌を治療又は予防するためのnat10モジュレーター

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
CA2635214A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
DK3091011T3 (en) 2006-04-07 2018-02-26 Vertex Pharma MODULATORS OF ATP BINDING CASSETTE TRANSPORT
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8283351B2 (en) 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
AU2008310097B2 (en) 2007-10-09 2013-05-16 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
WO2009051909A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
ES2445447T3 (es) 2007-11-16 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores de isoquinolina de transportadores de casete de unión a ATP
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131952A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising thiazole derivatives
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
WO2010088630A2 (en) * 2009-02-02 2010-08-05 Chromocell Corporation Cell lines expressing cftr and methods of using them
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
PL3835297T3 (pl) 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
RU2579370C2 (ru) 2010-04-07 2016-04-10 Вертекс Фармасьютикалз Инкорпорейтед Твердые формы 3-(2, 2-дифторбензо[d][1, 3] диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (zh) 2010-08-23 2013-06-12 弗特克斯药品有限公司 (R)-1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用
US20130303761A1 (en) 2010-09-14 2013-11-14 Instytut Biochemii I Biofizyki Pan Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012166654A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
CA2840393A1 (en) 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
JP2014533094A (ja) 2011-06-29 2014-12-11 ヤンセン ファーマシューティカ エヌ.ベー. プロ形態のマトリックスメタロプロテイナーゼの結晶構造及びアロステリックなプロセシング阻害剤
JP6182136B2 (ja) 2011-06-29 2017-08-16 ヤンセン ファーマシューティカ エヌ.ベー. マトリックスメタロプロテアーゼのアロステリックなプロセシング阻害因子を設計、選択及び/又は最適化するための方法
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
RU2644723C2 (ru) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
WO2013130669A1 (en) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
IL283276B1 (en) 2012-11-02 2024-01-01 Vertex Pharma Preparations containing 3-(6-(1-(2,2-difluorobenzo[1,3][D]dioxol-5-yl)cycloproponecarboxamide)-3-methylpyridin-2-yl)benzoic acid and N-(5-hydroxy- 2,4-ditert-butyl-phenyl)-4-oxo-H1-quinoline-3-carboxamide and their uses
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CA2969587A1 (en) 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2016123246A1 (en) 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey (thio, oxo and seleno) semicarbazone complexes with zinc and their use for treating cancer
WO2016123253A1 (en) * 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey Hydrazne derivatives for the treatment of cancer
US10604480B2 (en) 2015-01-27 2020-03-31 Rutgers, The State University Of New Jersey (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer
WO2016123250A1 (en) 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer
BR112017016205A2 (pt) * 2015-02-09 2018-03-27 Romani Luigina thymosin alpha 1 para uso no tratamento de fibrose cística
ITUB20153714A1 (it) * 2015-09-18 2017-03-18 Luigina Romani Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.
CA3001099A1 (en) * 2015-10-09 2017-04-13 Abbvie S.A.R.L. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
US11298348B2 (en) 2018-01-11 2022-04-12 Inserm (Institut National De La Sante Et De La Recherche Médicale) Combination treatment of sarcoglycanopathies
MX2021002653A (es) 2018-09-09 2021-09-23 Qanatpharma Ag Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares.
KR102399037B1 (ko) * 2020-01-06 2022-05-17 성균관대학교산학협력단 아민화된 아진의 신규한 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982002383A1 (en) * 1981-01-13 1982-07-22 Sakano Isao Novel thiazole compounds,process for their preparation,and medicinal composition containing same
JPS649935A (en) 1987-06-30 1989-01-13 Kyowa Hakko Kogyo Kk Remedy for hepatopathy
JPH07502014A (ja) * 1991-06-21 1995-03-02 ベーリンガー マンハイム イタリア エス.ピー.エイ. 気道に対して抗喘息性、抗炎症性活性を有する2−アミノ−4−アリール−チアゾール
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
SE0201837D0 (sv) * 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
WO2004098510A2 (en) 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy
WO2004110352A2 (en) * 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541367A (ja) * 2006-06-27 2009-11-26 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシス ピーエルエイ 2,4,5−三置換チアゾール化合物、それを含有する医薬組成物、並びにその調製及び医学的使用
JP2017511333A (ja) * 2014-04-03 2017-04-20 ケンブリッジ エンタープライズ リミテド ラミノパシー、老化及び癌を治療又は予防するためのnat10モジュレーター

Also Published As

Publication number Publication date
WO2006101740A2 (en) 2006-09-28
MX2007011512A (es) 2007-12-07
CA2600869A1 (en) 2006-09-28
US20080318984A1 (en) 2008-12-25
WO2006101740A3 (en) 2009-06-04
KR20070114820A (ko) 2007-12-04
CN101605543A (zh) 2009-12-16
AU2006227833A1 (en) 2006-09-28
RU2007138584A (ru) 2009-04-27
BRPI0608453A2 (pt) 2009-12-29
US8143295B2 (en) 2012-03-27
EP1863522A4 (en) 2010-11-10
IL185999A0 (en) 2008-08-07
EP1863522A2 (en) 2007-12-12

Similar Documents

Publication Publication Date Title
JP2008538107A (ja) 変異型cftrプロセシングの修正において活性を有する化合物及びその用途
US7696244B2 (en) Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US7939558B2 (en) Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
JP4977319B2 (ja) 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法
Lim et al. 14-3-3ζ coordinates adipogenesis of visceral fat
Pedemonte et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening
US7638543B2 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
El‐Sheikh et al. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4
US8389736B2 (en) Compounds having activity in correcting mutant-CFTR processing and uses thereof
CA2736441A1 (en) Pyrazolylthiazole compounds as .delta.f508-cystic fibrosis transmembrane conductance regulator correctors
US20180161313A1 (en) Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors
Hodges et al. Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice
US20230068698A1 (en) Combination therapy for cancer
US20040063695A1 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2009051910A1 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
JP2012502962A (ja) 肺の炎症および線維症の予防および/または治療のための尿酸レベルを低下させることができる化合物の使用
AU2014232030B2 (en) Therapeutic agent for systemic bone disease and use thereof
BR112020012972A2 (pt) uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística
Makarenko et al. Long-term facilitation of catecholamine secretion from adrenal chromaffin cells of neonatal rats by chronic intermittent hypoxia
RU2776477C2 (ru) Применение производных 1-фенил-2-пиридинилалкилового спирта при лечении муковисцидоза
JP5812382B2 (ja) Gata阻害剤を有効成分とする有機イオントランスポーター発現増強剤及びgata発現抑制剤
KR102215967B1 (ko) IRE1α 키나아제 활성화제를 유효성분으로 포함하는 단백질 형태 이상 질환의 예방 또는 치료용 조성물
Widjaja et al. IL11 stimulates ERK/P90RSK to inhibit LKB1/AMPK and activate mTOR in hepatocytes, the stroma and cancer cells
WO2022173334A2 (en) Methods, compositions and compounds for treating age-related diseases and conditions
US9073863B2 (en) Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080818

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20090512